Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology

Youssef, Mohamed; Veen, Fulco van der; Al-Inany, Hesham; Mochtar, Monique H.; Griesinger, G.; Mohesen, Mohamed N.; Aboulfoutouh, Ismail; Wely, Madelon van

doi:10.1002/14651858.cd008046.pub4

Cited by 244 publications

(206 citation statements)

References 87 publications

Supporting

Mentioning

178

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the routine use of a GnRH agonist as the lone trigger for final 4 oocyte maturation in fresh IVF autologous cycles was discouraged. It was considered that it could be useful for women who choose to avoid fresh transfers, women who donate oocytes to recipients or women who wish to freeze their eggs for later use in the context of fertility preservation [3]. However, it should be noted that the authors did not recognize that luteal support was the variable responsible for lower pregnancy rates because the luteal phase support differed among studies included in the Cochrane analysis.…”

Section: Introductionmentioning

confidence: 99%

Combined ovulation triggering with GnRH agonist and hCG in IVF patients

Kasum

Kurdija²,

Orešković

et al. 2016

Gynecological Endocrinology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Combined ovulation triggering with GnRH agonist and hCG in IVF patients

Kasum

Kurdija²,

Orešković

et al. 2016

Gynecological Endocrinology

View full text Add to dashboard Cite

“…52 2014 yılındaki bir Cochrane meta-analizinde GnRH agonistleri ile ovulasyonun tetiklenmesi HCG ile karşılaştırıldı-ğında OHSS insidansında azalma ile birlikte daha düşük gebelik ve canlı doğum oranları ile ilişkili bulunmuştur. 53 OPU işleminden 35-37 saat öncesinde eş zamanlı olarak standart doz HCG'ye ek olarak GnRH agonist uygulanması 'dual trigger' olarak adlandı-rılmaktadır. Lin ve ark.…”

Section: Hcg (üRiner/recombinant) R-lh Gnrh Agonistleriunclassified

Controlled Ovarian Stimulation in IVF Cycles

Gürgan¹,

Gülerman²,

Özyer³

2017

TJRMS

View full text Add to dashboard Cite

42n vitro fertilizasyon (IVF) sonrası ilk başarılı doğum, spontan ovulatuar siklusta tek bir oosit elde edilip tek embryo transferi yapılmasıyla sağlanmıştır. Ancak bu yöntemin başarı oranı dü-şüktür ve günümüzde klinisyenler çok sayıda follikülün senkron gelişimini sağlayacak ovaryan stimülasyon stratejilerinin kullanımını benimsemişlerdir. Kontrollü ovaryan stimülasyon (KOS), IVF tedavisi dahilinde overlerden en ideal sayı ve kalitede oosit elde etmek amacı ile aynı siklusta çok sayıda follikülün geliştirilmesidir. 1970'li yıllardaki ilk uygulamalardan itibaren KOS, IVF'in temel basamaklarından birini oluşturmaktadır. Oosit kalitesini ve canlı doğum oranlarını artırmak, düşük over rezervi olan hastalarda over yanıtını iyileştir-mek ve ovaryan hiperstimülasyon riskini azaltmak amacıyla çeşitli KOS protokolleri geliştirilmiştir. A An na ah h t ta ar r K Ke e l li i m me e l le er r: : İn vitro fertilizasyon; kontrollü ovaryan stimülasyon; protokol A AB BS S T TR RA AC CT T After the first live birth through a natural cycle in vitro fertilization (IVF) trial in 1978, advances in assisted reproductive techniques (ART) have been rapidly proceeded. Since then, more than 5 million pregnancies have been achieved worldwide by IVF and other modified techniques generally named as ART. As the experience and the success rates have increased, the indications for ART also expands. With the advances in reproductive biology, laboratory and pharmaceutical sciences, there is increasing attention on the importance of controlled ovarian stimulation (COS) to the IVF outcomes. Individualized COS (iCOS ) practices will improve IVF outcomes and safety issues. The aim of this review is to go through the fundamentals of COS and its best practices in ART.

show abstract

“…GnRH agonist triggering has been associated with luteal phase defects, presumably due to excessive negative steroid feedback [37][38][39]. Two consecutive Cochrane reviews by the same author state that: BGnRH agonist triggering is associated with a lower ongoing pregnancy rate compared with conventional hCG^ [29,40]. This conclusion was qualified as premature and mistaken based on the following: (1) Cochrane reviews should not be conducted in the research phase when new concepts are being developed, and (2) the authors missed the fact that the variable that affects results is luteal phase support itself and not the use of GnRH agonist trigger for final oocyte maturation [39].…”

Section: Freeze-all-why?mentioning

confidence: 99%

The state of “freeze-for-all” in human ARTs

Basile

Garcia-Velasco

2016

J Assist Reprod Genet

View full text Add to dashboard Cite

The recent development of vitrification technologies and the good outcomes obtained in assisted reproduction technologies have supported new indications for freezing and segmentation of treatment. Beyond OHSS prevention and avoidance of embryo transfers in the setting of an adverse endocrinological profile or endometrial cavity, we have witnessed a trend to shift fresh embryo transfers to frozen embryo transfers in many programs. We critically review the available evidence and suggest that freeze-all is not Bfor all,b ut should be individualized.

show abstract

Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology

Cited by 244 publications

References 87 publications

Combined ovulation triggering with GnRH agonist and hCG in IVF patients

Combined ovulation triggering with GnRH agonist and hCG in IVF patients

Controlled Ovarian Stimulation in IVF Cycles

The state of “freeze-for-all” in human ARTs

Contact Info

Product

Resources

About